Sanofi share remains close to its lowest level since 2018, at the bottom of the CAC 40
The pharmaceutical laboratory is declining slightly in mid-afternoon, within a rising CAC 40. The value remains at the bottom of the index ranking, following a difficult quarter and a multi-year low touched in early October.
A session in decline within a rising CAC 40, approaching the MA20
The stock is down 0.46% at €71.83, while the CAC 40 gains 0.4% and the SBF 120 advances 0.47%. Sanofi is among the largest declines on the index, behind only Michelin, Schneider Electric, and Eurofins Scientific. The price is in contact with the MA20 at €72.05, following a rebound of 1.27% over seven days, which does not erase the decline of 3.21% over the month. The MA50 at €74.52 and the MA200 at €77.04 are both above the current price.
The stock had broken through its support at €71.47 on October 2nd to sign a low unseen since 2018, before rebounding. The next support is at €69.99, resistance at €76.26. On the regulatory front, Le Revenu reported on October 14th that the laboratory was escaping an EU fine that could reach 10% of its revenue, contextual information that does not explain today's movement.
A decline over twelve months that contrasts with the performance of comparable companies
Over one year, the stock is down 14.77%, and 5.81% over three months, far from the momentum of Eurofins Scientific, which gains 13.35% over the quarter despite a slight decline today. Nanobiotix, another healthcare value, is down 41.16% over three months. The RSI at 48.3 is neutral, and the MACD histogram at 0.19 remains close to zero, without a clear reversal signal.
According to the consensus of surveyed analysts, the stock is trading at approximately 8.3 times the earnings of the current fiscal year, with earnings per share growth expected at 5.2%. The group expanded its collaboration with Regeneron on October 1st to four new antibodies, with an initial payment of one billion dollars.
